The Hip in Muscular Dystrophy

  • Deborah M. Eastwood


The muscular dystrophies (MD) are a group of inherited conditions characterized by a progressive muscle weakness and increasing disability. The most common and well-known is Duchenne muscular dystrophy (DMD). DMD is essentially the only MD associated with hip problems.

The medical management of DMD has changed over recent years, particularly with the use of steroid medication. This has lengthened life but is associated with other problems that adversely affect quality of life.

Advances have been made in the understanding of dystrophin production in DMD and Becker Muscular Dystrophy. Trials of molecular based therapies including gene replacement via a viral vector have taken place although there are substantial challenges to translation into widespread clinical practice.

Compared to other neuromuscular diseases, hip problems are unusual in DMD and there are no accepted guidelines for the management of hip contractures or hip subluxation/dislocation in this patient group.


Duchenne muscular dystrophy Becker muscular dystrophy Dystrophin Hip Scoliosis 


  1. 1.
    Birnkrant DJ, Bushby K, Bann CM et al for the DMD Care Considerations Working Group. Diagnosis and management of Duchenne muscular dystrophy part 1: diagnosis and neuromuscular rehabilitation, endocrine and gastrointestinal and nutritional management. Lancet. 2018;17:251–67.CrossRefGoogle Scholar
  2. 2.
    Ryder S, Leadley RM, Armstrong N, Westwood M, de Kock S, Butt T, Jain M, Kleijnen J. The burden, epidemiology, costs and treatment for Duchenne muscular dystrophy: an evidence review. Orphanet J Rare Dis. 2017;112:79–100.CrossRefGoogle Scholar
  3. 3.
    Matthews E, Brassington R, Kuntzer T, Jichi F, Mansur AY. Corticosteroids for the treatment of Duchenne muscular dystrophy. Cochrane Database Syst Rev. 2016;5(5):CD003725.Google Scholar
  4. 4.
    Dowling JJ, Gonorazky HD, Cohn RD, Campbell C. Treating pediatric neuromuscular disorders: the future is now. Am J Med Genet. 2018;176:804–41.CrossRefGoogle Scholar
  5. 5.
    Birnkrant DJ, Bushby K, Bann CM et al for the DMD Care Considerations Working Group. Diagnosis and management of Duchenne muscular dystrophy part 2: respiratory, cardiac, bone health and orthopaedic management. Lancet. 2018;17:347–61.CrossRefGoogle Scholar
  6. 6.
    Judge LM, Haraguchi M, Chamberlain JS. Dissecting the signalling and mechanical functions of the dystrophin-glycoprotein complex. J Cell Sci. 2006;119:1537–46.CrossRefGoogle Scholar
  7. 7.
    Sussman MD. Duchenne muscular dystrophy. J Am Acad Orthop Surg. 2002;10:138–51.CrossRefGoogle Scholar
  8. 8.
    Rodino-Klapac LR, Mendell JR, Sahenk Z. Update on the treatment of Duchenne muscular dystrophy. Curr Neurol Neurosci Rep. 2013;13:332.CrossRefGoogle Scholar
  9. 9.
    Chan KG, Galasko CS, Delaney C. Hip subluxation and dislocation in Duchenne muscular dystrophy. J Pediatr Orthop B. 2001;10:219–25.PubMedGoogle Scholar
  10. 10.
    Birnkrant DJ, Bushby K, Bann CM et al for the DMD Care Considerations Working Group. Diagnosis and management of Duchenne muscular dystrophy part 3: primary care, emergency management, psychosocial care and transitions of care across the lifespan. Lancet. 2018;17:1–11.CrossRefGoogle Scholar
  11. 11.
    Heberer K, Fowler E, Staudt L, Sienko S, Buckon CE, Bagley A, Sison-Williamson M, McDonald CM, Sussman M. Hip kinetics during gait are clinically meaningful outcomes in young boys with Duchenne muscular dystrophy. Gait Posture. 2016;48:159–64.CrossRefGoogle Scholar
  12. 12.
    Wallace GB, Newton RW. Gower’s sign revisited. Arch Dis Child. 1989;64:1317–9.CrossRefGoogle Scholar
  13. 13.
    Chang RF, Mubarak SJ. Pathomechanics of Gowers’ sign. A video analysis of a spectrum of Gowers’ maneuvers. Clin Orthop Relat Res. 2012;470:1987–91.CrossRefGoogle Scholar
  14. 14.
    Lebel DE, Corston JA, McAdam LC, Biggar WD, Alman BA. Glucocorticoid treatment for the prevention of scoliosis in children with Duchenne muscular dystrophy: long term follow-up. J Bone Joint Surg Am. 2013;95:1057–61.CrossRefGoogle Scholar
  15. 15.
    Archer JE, Gardner AC, Roper HP, Chikermane AA, Tatman AJ. Duchenne muscular dystrophy: the management of scoliosis. J Spine Surg. 2016;2:185–94.CrossRefGoogle Scholar
  16. 16.
    Buckon C, Sienko S, Bagley A, Sison-Williamson M, Fowler E, Staudt L, Heberer K, McDonald CM, Sussman M. Can quantitative muscle strength and functional motor ability differentiate the influence of age and corticosteroids in ambulatory boys with Duchenne muscular dystrophy? PLoS Curr. 2016;8:8.Google Scholar
  17. 17.
    Barp A, Bello L, Caumo L, Campadello P, Semplicini C, Lazzarotto A, Sorarù G, Calore C, Rampado A, Motta R, Stramare R, Pegoraro E. Muscle MRI and functional outcome measures in Becker muscular dystrophy. Sci Rep. 2017;7:16060.CrossRefGoogle Scholar
  18. 18.
    Patel J, Shapiro F. Simultaneous progression patterns of scoliosis, pelvic obliquity, and hip subluxation/dislocation in non-ambulatory neuromuscular patients: an approach to deformity documentation. J Child Orthop. 2015;9:345–56.CrossRefGoogle Scholar
  19. 19.
    Griggs R.. Finding the optimum regiment for Duchenne muscular dystrophy (FOR DMD). https://clinicaltrials.gove/ct2/show/NCT01603407. Accessed 20 Apr 2018.
  20. 20.
    Bell JM, Shields MD, Watters J, Hamilton A, Beringer T, Elliott M, Quinlivan R, Tirupathi S, Blackwood B. Interventions to prevent and treat corticosteroid-induced osteoporosis and prevent osteoporotic fractures in Duchenne muscular dystrophy. Cochrane Database Syst Rev. 2017;24(1):CD010899.Google Scholar
  21. 21.
    Srinivasan R, Rawlings D, Wood CL, Cheetham T, Moreno AC, Mayhew A, Eagle M, Guglieri M, Starub V, Owen C, Bushby K, Sarkozy A. Prophylactic oral bisphosphonate therapy in Duchenne muscular dystrophy. Muscle Nerve. 2016;54:79–85.CrossRefGoogle Scholar
  22. 22.
    Buckner JL, Bowden SA, Mahan JD. Optimising bone health in Duchenne muscular dystrophy. Int J Endocinol. 2015;2015:928385.Google Scholar
  23. 23.
    Gordon KE, Dooley JM, Sheppard KM, MacSween J, Esser MJ. Impact of bisphosphonates on survival for patients with Duchenne muscular dystrophy. Pediatrics. 2011;127:e353–8.CrossRefGoogle Scholar
  24. 24.
    Sbrocchi AM, Rauch F, Jacob P, McCormick A, McMillan HJ, Matzinger MA, Ward LM. The use of intravenous bisphosphonate therapy to treat vertebral fractures due to osteoporosis among boys with Duchenne muscular dystrophy. Osteoporosis Int. 2012;23:2803–11.CrossRefGoogle Scholar
  25. 25.
    Houston C, Matthews K, Shibli-Rahhal A. Bone density and alendronate effects in Duchenne muscular dystrophy patients. Muscle Nerve. 2014;49:506–11.CrossRefGoogle Scholar
  26. 26.
    Frischhut B, Krismer M, Stoeckl B, Landauer F, Auckenthaler T. Pelvic tilt in neuromuscular disorders. J Pediatr Orthop B. 2000;9:221–8.CrossRefGoogle Scholar
  27. 27.
    Scannell BP, Yaszay B, Bartley CE, Newton PO, Mubarak SJ. Surgical correction of scoliosis in patients with Duchenne muscular dystrophy: 30-year experience. J Pediatr Orthop. 2017;37:464–9.CrossRefGoogle Scholar
  28. 28.
    Galasko CS, Williamson JB, Delaney CM. Lung function in Duchenne muscular dystrophy. Eur Spine J. 1995;5:263–7.CrossRefGoogle Scholar
  29. 29.
    Rideau Y, Duport G, Delaubier A, Guillou C, Renardel-Irani A, Bach JR. Early treatment to preserve quality of locomotion for children with Duchenne muscular dystrophy. Semin Neurol. 1995;15:9–1.CrossRefGoogle Scholar
  30. 30.
    Forst J, Forst R. Surgical treatment of Duchenne muscular dystrophy patients in Germany: the present situation. Acta Myol. 2012;31:21–3.PubMedPubMedCentralGoogle Scholar
  31. 31.
    Smith SE, Green NE, Cole RJ, Robison JD, Fenichel GM. Prolongation of ambulation in children with Duchenne muscular dystrophy by subcutaneous lower limb tenotomy. J Pediatr Orthop. 1993;13:336–40.CrossRefGoogle Scholar
  32. 32.
    Rideau YM. Requiem: memories by a myologist. Acta Myol. 2012;31:48–60.PubMedPubMedCentralGoogle Scholar
  33. 33.
    Cheuk DK, Wong V, Wriage E, Baxter P, Cole A. Surgery for scoliosis in Duchenne muscular dystrophy. Cochrane Database Syst Rev. 2015;1(10):CD005375.Google Scholar
  34. 34.
    Suk KS, Lee BH, Moon SH, Choi YC, Shin DE, Ha JW, Song KM, Kim HS. Functional outcomes in Duchenne muscular dystrophy scoliosis: comparison of the differences between surgical and nonsurgical management. J Bone Joint Surg Am. 2014;96:409–15.CrossRefGoogle Scholar
  35. 35.
    Canavese F, Sussman MD. Strategies of hip management in neuromuscular disorders: Duchenne muscular dystrophy, spinal muscular atrophy, charcot-marie-tooth disease and arthrogryposis multiplex congenita. Hip Int. 2009;19(Suppl 6):S46–52.CrossRefGoogle Scholar
  36. 36.
    Duckworth AD, Mitchell MJ, Tsirikos AI. Incidence and risk factors for postoperative complications after scoliosis surgery in patients with Duchenne muscular dystrophy: a comparison with other neuromuscular conditions. Bone Joint J. 2014;96:943–9.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Deborah M. Eastwood
    • 1
    • 2
  1. 1.Great Ormond St. Hospital for ChildrenLondonUK
  2. 2.The Catterall UnitThe Royal National Orthopaedic HospitalStanmoreUK

Personalised recommendations